TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
QIAGEN DNA Synthesis AB
Closing information (x1000 NOK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
148,493
|
101,384
|
74,216 |
| Financial expenses |
7,632
|
9,058
|
4,693 |
| Earnings before taxes |
-2,688
|
-40,125
|
-50,323 |
| EBITDA |
16,548
|
-20,073
|
-38,047 |
| Total assets |
155,718
|
170,759
|
150,901 |
| Current assets |
76,258
|
87,680
|
84,987 |
| Current liabilities |
120,401
|
133,414
|
132,953 |
| Equity capital |
35,317
|
37,344
|
17,948 |
| - share capital |
206
|
203
|
189 |
| Employees (average) |
90
|
99
|
105 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
22.7%
|
21.9%
|
11.9% |
| Turnover per employee |
1,650
|
1,024
|
707 |
| Profit as a percentage of turnover |
-1.8%
|
-39.6%
|
-67.8% |
| Return on assets (ROA) |
3.2%
|
-18.2%
|
-30.2% |
| Current ratio |
63.3%
|
65.7%
|
63.9% |
| Return on equity (ROE) |
-7.6%
|
-107.4%
|
-280.4% |
| Change turnover |
45,281
|
21,902
|
-6,704 |
| Change turnover % |
44%
|
28%
|
-8% |
| Chg. No. of employees |
-9
|
-6
|
8 |
| Chg. No. of employees % |
-9%
|
-6%
|
8% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.